GT Biopharma Inc (GTBP) - Total Liabilities
Based on the latest financial reports, GT Biopharma Inc (GTBP) has total liabilities worth $2.42 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore GT Biopharma Inc equity growth rate to track the company's year-over-year net asset growth rate.
GT Biopharma Inc - Total Liabilities Trend (1983–2025)
This chart illustrates how GT Biopharma Inc's total liabilities have evolved over time, based on quarterly financial data. See GTBP FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
GT Biopharma Inc Competitors by Total Liabilities
The table below lists competitors of GT Biopharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Binasat Communications Bhd
KLSE:0195
|
Malaysia | RM58.05 Million |
|
Noviqtech Ltd
AU:NVQ
|
Australia | AU$1.38 Million |
|
Origin Agritech Limited
STU:39O1
|
Germany | €168.09 Million |
|
Oxbridge Re Holdings Ltd
NASDAQ:OXBR
|
USA | $2.12 Million |
|
Jeonjinbio Co. Ltd
KQ:110020
|
Korea | ₩1.27 Billion |
|
Australian Oilseeds Holdings Limited Ordinary Shares
NASDAQ:COOT
|
USA | $29.72 Million |
|
Dfcity Group Bhd
KLSE:5165
|
Malaysia | RM24.25 Million |
|
Karnalyte Resources Inc.
TO:KRN
|
Canada | CA$2.29 Million |
Liability Composition Analysis (1983–2025)
This chart breaks down GT Biopharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see GTBP market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GT Biopharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GT Biopharma Inc (1983–2025)
The table below shows the annual total liabilities of GT Biopharma Inc from 1983 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.32 Million | -60.71% |
| 2024-12-31 | $5.90 Million | -11.02% |
| 2023-12-31 | $6.63 Million | +32.61% |
| 2022-12-31 | $5.00 Million | -51.24% |
| 2021-12-31 | $10.26 Million | -70.77% |
| 2020-12-31 | $35.09 Million | +78.09% |
| 2019-12-31 | $19.71 Million | +40.47% |
| 2018-12-31 | $14.03 Million | +423.67% |
| 2017-12-31 | $2.68 Million | -85.86% |
| 2016-12-31 | $18.95 Million | -62.57% |
| 2015-12-31 | $50.62 Million | +66.18% |
| 2014-12-31 | $30.46 Million | +370.02% |
| 2013-12-31 | $6.48 Million | -1.23% |
| 2012-12-31 | $6.56 Million | +25.47% |
| 2011-12-31 | $5.23 Million | -7.50% |
| 2010-12-31 | $5.65 Million | -20.46% |
| 2009-12-31 | $7.11 Million | +66.46% |
| 2008-12-31 | $4.27 Million | +32.28% |
| 2007-12-31 | $3.23 Million | -58.63% |
| 2006-12-31 | $7.80 Million | +82.80% |
| 2005-12-31 | $4.27 Million | +59.25% |
| 2004-12-31 | $2.68 Million | +145.20% |
| 2003-12-31 | $1.09 Million | +42.50% |
| 2002-12-31 | $767.00K | -35.44% |
| 2001-12-31 | $1.19 Million | -23.45% |
| 2000-12-31 | $1.55 Million | -37.80% |
| 1999-12-31 | $2.50 Million | -37.63% |
| 1998-12-31 | $4.00 Million | -31.03% |
| 1997-12-31 | $5.80 Million | +65.71% |
| 1996-12-31 | $3.50 Million | -37.50% |
| 1995-12-31 | $5.60 Million | +24.44% |
| 1994-12-31 | $4.50 Million | +1400.00% |
| 1993-12-31 | $300.00K | -50.00% |
| 1992-12-31 | $600.00K | +200.00% |
| 1991-12-31 | $200.00K | 0.00% |
| 1990-12-31 | $200.00K | -60.00% |
| 1989-12-31 | $500.00K | +66.67% |
| 1988-12-31 | $300.00K | +50.00% |
| 1987-12-31 | $200.00K | -60.00% |
| 1986-12-31 | $500.00K | +400.00% |
| 1985-12-31 | $100.00K | -66.67% |
| 1984-12-31 | $300.00K | -25.00% |
| 1983-12-31 | $400.00K | -- |
About GT Biopharma Inc
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, tha… Read more